Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interchangeability of DPT-IPV + Hib vs GOBIK pentavalent booster
jRCT1031230708Completed
- Sponsor
- Research Foundation for Microbial Diseases of Osaka University
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of vilobelimab in Haemophilus influenzae type b disease (Hib), pertussis, diphtheria and 2 more (2 arms), sponsored by Research Foundation for Microbial Diseases of Osaka University. Primary endpoint: Anti-PRP antibody prevalence ≥1 mcg/mL. Started May 2024; status: completed.
02
Drugs
vilobelimab
03
Conditions
Haemophilus influenzae type b disease (Hib)pertussisdiphtheriaTetanuspoliomyelitis
Beyond the preview
Go deeper on jRCT1031230708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230708.